Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALRN

ALRN - Aileron Therapeutics Inc Stock Price, Fair Value and News

$2.01 
Market Closed

Price Targets

ALRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALRN Price Action

ALRN RSI Chart

ALRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALRN Valuation

Market Cap

52.8M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

238

Price/Free Cashflow

-2.5

ALRN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALRN Fundamentals

ALRN Revenue

Revenue (TTM)

222.0K

ALRN Earnings

Earnings (TTM)

-58.9M

Earnings Growth (Yr)

4.55%

Earnings Growth (Qtr)

18.19%

ALRN Profitability

Return on Equity

-127.48%

Return on Assets

-109.64%

Free Cashflow Yield

-39.95%

ALRN Investor Care

Shares Dilution (1Y)

21.33%

Diluted EPS (TTM)

-2.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
201700222.0K0
20160000
Get all data in R, Python etc through our Historical Stock Data APIs

About Aileron Therapeutics Inc

ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEaileronrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Aileron Therapeutics Inc Frequently Asked Questions

ALRN is the stock ticker symbol of Aileron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Oct 31 2025, market cap of Aileron Therapeutics Inc is 52.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALRN's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALRN is over valued or under valued. Whether Aileron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aileron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALRN.

As of Fri Oct 31 2025, ALRN's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 238. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALRN PE ratio will change depending on the future growth rate expectations of investors.